
USD
+$0.00
(+0.00%
)At Close (As of Nov 28, 2025)
$4.58B
Market Cap
22.3
P/E Ratio
0.86
EPS
$25.67
52 Week High
$13.50
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $220M |
| Total Revenue | $426M |
| Cost Of Revenue | $207M |
| Costof Goods And Services Sold | $207M |
| Operating Income | $139M |
| Selling General And Administrative | $74M |
| Research And Development | $1.8M |
| Operating Expenses | $81M |
| Investment Income Net | - |
| Net Interest Income | -$12M |
| Interest Income | $2.1M |
| Interest Expense | $14M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $8M |
| Income Before Tax | $126M |
| Income Tax Expense | -$72M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $198M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $140M |
| Ebitda | $148M |
| Net Income | $198M |
| Field | Value (USD) |
|---|---|
| Total Assets | $489M |
| Total Current Assets | $331M |
| Cash And Cash Equivalents At Carrying Value | $103M |
| Cash And Short Term Investments | $103M |
| Inventory | $170M |
| Current Net Receivables | $50M |
| Total Non Current Assets | $157M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $460K |
| Intangible Assets Excluding Goodwill | $460K |
| Goodwill | $3.5M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $8M |
| Other Non Current Assets | - |
| Total Liabilities | $140M |
| Total Current Liabilities | $56M |
| Current Accounts Payable | $20M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $1.2M |
| Total Non Current Liabilities | $84M |
| Capital Lease Obligations | $9.8M |
| Long Term Debt | $72M |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $82M |
| Other Current Liabilities | $30M |
| Other Non Current Liabilities | $1.7M |
| Total Shareholder Equity | $349M |
| Treasury Stock | - |
| Retained Earnings | -$309M |
| Common Stock | $24K |
| Common Stock Shares Outstanding | $243M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $119M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $8M |
| Capital Expenditures | $8.6M |
| Change In Receivables | - |
| Change In Inventory | $2.7M |
| Profit Loss | - |
| Cashflow From Investment | -$8.6M |
| Cashflow From Financing | -$58M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $198M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $220M |
| Total Revenue | $426M |
| Cost Of Revenue | $207M |
| Costof Goods And Services Sold | $207M |
| Operating Income | $139M |
| Selling General And Administrative | $74M |
| Research And Development | $1.8M |
| Operating Expenses | $81M |
| Investment Income Net | - |
| Net Interest Income | -$12M |
| Interest Income | $2.1M |
| Interest Expense | $14M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $8M |
| Income Before Tax | $126M |
| Income Tax Expense | -$72M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $198M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $140M |
| Ebitda | $148M |
| Net Income | $198M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
ADMA Biologics, Inc. is a biopharmaceutical company based in Ramsey, New Jersey, specializing in the development and commercialization of plasma-derived therapies for immunodeficiencies and infectious diseases. The company employs proprietary production technologies to produce high-quality therapeutic products, thereby enhancing patient outcomes in a significant healthcare market. With a strong pipeline and a dedication to addressing critical medical needs, ADMA is well-positioned for growth in the evolving landscape of biopharmaceuticals.